Opinion on this? Would use it next to Pyrilutamide 0.9% Treatment 3/17/2026
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The user is considering using these alongside Pyrilutamide 0.9%.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity 1 yr 4 months update with topical finasteride then FUE transplant
User tried topical finasteride mixed with minoxidil, Nizoral shampoo, oral minoxidil, and FUE hair transplant for hair loss. User asks when it's safe to trim hair after transplant and considers trying RU58841 or pyrilutamide.
community If you are wondering, YES, you will go through a shed if you switch Minoxidil brands.
Switching from Kirkland minoxidil foam to a topical finasteride/minoxidil solution can cause significant hair shedding. The user also uses dutasteride, RU58841, and pyrilutamide in their treatment regimen.
community 8 years of Finasteride and Minoxidil (includes a photo)
User has used Finasteride, Minoxidil, and derma roller for 8 years to treat hair loss but is still losing the battle. Others suggest trying Dutasteride, oral Minoxidil, RU58841, or considering a hair transplant.
community Is this regrowth? My doctor took these photos and said I looked better.
The conversation humorously discusses an extensive and exaggerated hair loss treatment regimen, including finasteride, dutasteride, minoxidil, pyrilutamide, RU58841, and various other therapies. Despite the numerous treatments, the effectiveness is questioned, and the user humorously considers adding more minoxidil.
community Guys, we finally have an alternative to finasteride
A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.
community Topical Minoxidil is a pain in the ass for diffuse thinners
Topical minoxidil being a difficult product to apply, with users considering finasteride, RU58841, and oral minoxidil as alternative treatments for diffuse thinning hair. Other advice includes shaving the head in the first 3 months of using minoxidil and finding ways to apply it without saturating the hair.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Investigational medications in the treatment of alopecia
This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.
research Minoxidil: effectiveness and prospects for use in the treatment of androgenetic alopecia
Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.
research Тіе Modern treatment of androgenetic alopecia
This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
research Андрогенетическая алопеция: патогенетические механизмы и подходы к лечению
This article reviews the pathophysiology and limited effectiveness of current treatments for androgenic alopecia, including finasteride, minoxidil, botulinum toxin A, and platelet-rich plasma, and highlights the need for new therapeutic approaches; it reports no new clinical findings.